Encrypted login | home

Program Information

Clinical Performance Evaluation of a Phase II Proton CT Scanner

R Schulte

A Mandapaka1 , A Ghebremedhin1 , D Farley1 , V Giacometti1 , N Vence1 , V Bashkirov1 , T Plautz2 , A Zatserklyaniy2 , R Johnson2 , H Sadrozinski2 , B Patyal1 , R Schulte1*, (1) Loma Linda Univ Medical Center, Loma Linda, CA, (2) University of California Santa Cruz, Santa Cruz, CA


SU-E-J-35 Sunday 3:00PM - 6:00PM Room: Exhibit Hall

Purpose: To develop the methodology to evaluate the clinical performance of a Phase II Proton CT scanner

Methods: Range errors on the order of 3%-5% constitute a major uncertainty in current charged particle treatment planning based on Hounsfield Unit (HU)-relative stopping power (RSP) calibration curves. Within our proton CT collaboration, we previously developed and built a Phase I proton CT scanner that provided a sensitive area of 9 cm (axial) x 18 cm (in-plane). This scanner served to get initial experience with this new treatment planning tool and to incorporate lessons learned into the next generation design. A Phase II scanner was recently completed and is now undergoing initial performance testing. It will increase the proton acquisition rate and provide a larger detection area of 9 cm x 36 cm. We are now designing a comprehensive evaluation program to test the image quality, imaging dose, and range uncertainty associated with this scanner. The testing will be performed along the lines of AAPM TG 66.

Results: In our discussion of the evaluation protocol we identified the following priorities. The image quality of proton CT images, in particular spatial resolution and low-density contrast discrimination, will be evaluated with the Catphan600 phantom. Initial testing showed that the Catphan uniformity phantom did not provide sufficient uniformity; it was thus replaced by a cylindrical water phantom. The imaging dose will be tested with a Catphan dose module, and compared to a typical cone beam CT dose for comparable image quality. Lastly, we developed a dedicated dosimetry range phantom based on the CIRS pediatric head phantom HN715.

Conclusion:A formal evaluation of proton CT as a new tool for proton treatment planning is an important task. The availability of the new Phase II proton CT scanner will allow us to perform this task.

Funding Support, Disclosures, and Conflict of Interest: This research is supported by the National Institute of Biomedical Imaging and Bioengineering of the NIH under award number R01EB013118. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH

Contact Email: